You are viewing a preview of this job. Log in or register to view more details about this job.

Clinical Research Internship - Nexcella - Sacramento

Immix Biopharma, Inc.
Email

We are looking for students in a life science based major, a graduation year of 2027 - 2029, and available to start in May 2026.

 

Location: Sacramento, CA (WORK WILL BE ONSITE)

Part time: 16-24 hours weekly, Flexible schedule

Pay: $20/hr

 

Our 3 Core Values 
• Intelligence
• Integrity
• Initiative

Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!
 

Responsibilities:

  • Check-in incoming raw materials for the laboratory
  • Receive incoming patient samples
  • Perform routine inventory counts of lab and office supplies
  • Check expiration dates on inventory 
  • Pack central laboratory collection supply kits
  • Break down and disposal of sample shipment boxes
  • Organize and scan various laboratory documentation
  • Assist with various lab tasks on occasion 

Minimum Qualifications:

  • GPA of 3.0 or above
  • Life Science Based Major (Biology, Biochemistry, Microbiology, etc)
  • Basic knowledge of Microsoft Office applications and Adobe
  • Laboratory experience gained through coursework or previous employment 
  • Ability to commute to Sacramento, CA
  • Ability to perform all tasks as described above, these tasks require sitting and standing for long periods of time 

 

Nexcella, Inc

Nexcella, Inc. is a subsidiary of Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. Interim results were presented at ASCO 2025 in an oral presentation by Heather Landau, M.D. of Memorial Sloan Kettering Cancer Center. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.nexcella.com and www.BeProactiveInAL.com.